Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)
8.68
+0.84 (10.71%)
At close: Sep 23, 2026
SHA:688238 Revenue
Shanghai Obio Technology (Group) Corp. had revenue of 71.25M CNY in the quarter ending June 30, 2026, with 6.33% growth. This brings the company's revenue in the last twelve months to 269.63M, up 5.76% year-over-year. In the year 2025, Shanghai Obio Technology (Group) Corp. had annual revenue of 267.70M with 7.88% growth.
Revenue (ttm)
269.63M
Revenue Growth
+5.76%
P/S Ratio
20.29
Revenue / Employee
372.93K
Employees
723
Market Cap
5.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 267.70M | 19.55M | 7.88% |
| Dec 31, 2024 | 248.15M | 43.34M | 21.16% |
| Dec 31, 2023 | 204.81M | -86.50M | -29.69% |
| Dec 31, 2022 | 291.30M | 36.36M | 14.26% |
| Dec 31, 2021 | 254.95M | 112.18M | 78.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 3.00B |
| Wuhan Hvsen Biotechnology | 1.72B |
| Xiangxue Pharmaceutical | 1.48B |
| Kexing Biopharm | 1.44B |
| Shenzhen Weiguang Biological Products | 1.20B |
| ChemPartner PharmaTech | 1.16B |
| Boji Medical Technology | 961.34M |
| Beijing Konruns Pharmaceutical | 917.05M |